Protection of exendin-4 analogue in early experimental diabetic retinopathy

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 247, Issue 5, 2009, Pages 699-706

  Zhang, Yu ^a   Wang, Qingping ^a   Zhang, Jingfa ^b,c   Lei, Xia ^b   Xu, Guo Tong ^b,c   Ye, Wen ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Diabetic retinopathy; Electroretinogram; Exendin 4; Exendin 4 analogue; GLP 1R

Indexed keywords

EXENDIN 4; EXENDIN 4 ANALOGUE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; MESSENGER RNA; SODIUM CHLORIDE; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; B WAVE; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; ELECTRORETINOGRAM; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; RNA ISOLATION; WESTERN BLOTTING;

ANIMALS; BLOOD GLUCOSE; BLOTTING, WESTERN; CELL COUNT; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; ELECTRORETINOGRAPHY; GLUCAGON-LIKE PEPTIDE 1; HYPOGLYCEMIC AGENTS; IMMUNOENZYME TECHNIQUES; INJECTIONS, SUBCUTANEOUS; MALE; PEPTIDES; POLYMERASE CHAIN REACTION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCAGON; RETINA; RETINAL PHOTORECEPTOR CELL INNER SEGMENT; RETINAL PHOTORECEPTOR CELL OUTER SEGMENT; RNA, MESSENGER; VENOMS;

EID: 64449087059     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-008-1004-3     Document Type: Article

References (41)

1. Abraham EJ, Leech CA, Lin JC, Zulewski H, Habener JF (2002) Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. Endocrinology 143:3152-3161
2. Antonetti DABA, Bronson SK, Freeman WM, Gardner TW, Jefferson LS, Kester M, Kimball SR, Krady JK, LaNoue KF, Norbury CC, Quinn PG, Sandirasegarane L, Simpson IA, JDRF Diabetic Retinopathy Center Group (2006) Diabetic retinopathy: Seeing beyond glucose-induced microvascular disease. Diabetes 55:2401-2411
3. Barber AJ (2003) A new view of diabetic retinopathy: A neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry 27:283-290
4. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM (2005) Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54:146-151
5. Bresnick GH, Palta M (1987) Oscillatory potential amplitudes. Relation to severity of diabetic retinopathy. Arch Ophthalmol 105:929-933
6. Buteau J, Roduit R, Susini S, Prentki M (1999) Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 42:856-864
7. Drucker DJ (2001) Minireview: The glucagon-like peptides. Endocrinology 142:521-527
8. Dupre J (2005) Glycaemic effects of incretins in Type 1 diabetes mellitus: A concise review, with emphasis on studies in humans. Regul Pept 128:149-157
9. Dupre J, Behme MT, McDonald TJ (2004) Exendin-4 normalized postcibal glycemic excursions in Type 1 diabetes. J Clin Endocrinol Metab 89:3469-3473
10. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, Bland RJ, Klugmann M, Banks WA, Drucker DJ, Haile CN (2003) Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 9:1173-1179
11. Fletcher EL, Phipps JA, Ward MM, Puthussery T, Wilkinson-Berka JL (2007) Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy. Curr Pharm Des 13:2699-2712
12. Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Levison SW (2002) Diabetic retinopathy: More than meets the eye. Surv Ophthalmol 47(Suppl 2):S253-262
13. Gershengorn MC, Hardikar AA, Wei C, Geras-Raaka E, Marcus-Samuels B, Raaka BM (2004) Epithelial-to-mesenchymal transition generates proliferative human islet precursor cells. Science 306:2261-2264
14. Goke R, Linn T, Schmidt H, Krause M, Eng J et al (1993) Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 268:19650-19655
15. Greig NHHH, De Ore KA, Jani D, Wang Y, Zhou J et al (1999) Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia 42:45-50
16. Guerci B, Martin CS (2008) Exenatide: Its position in the treatment of type 2 diabetes. Ann Endocrinol (Paris) 69:201-209
17. Hancock HA, Kraft TW (2004) Oscillatory potential analysis and ERGs of normal and diabetic rats. Invest Ophthalmol Vis Sci 45:1002-1008
18. Harkavyi A, Abuirmeileh A, Lever R, Kingsbury AE, Biggs CS, Whitton PS (2008) Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J Neuroinflammation 5:19
19. Holopigian K, Greenstein VC, Seiple W, Hood DC, Ritch R (2000) Electrophysiologic assessment of photoreceptor function in patients with primary open-angle glaucoma. J Glaucoma 9:163-168
20. Holst JJ (2002) Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev 18:430-441
21. James F, List HH, Habener JF (2006) Glucagon-like peptide-1 receptor and proglucagon expression in mouse skin. Regulatory Peptides 134:149-157
22. Juen S, Kieselbach GF (1990) Electrophysiological changes in juvenile diabetics without retinopathy. Arch Ophthalmol 108:372-375
23. Kieffer TJ, Francis Habener J (1999) The Glucagon-like peptides. Endocr Rev 20:876-913
24. Layton CJ, Safa R, Osborne NN (2007) Oscillatory potentials and the b-Wave: Partial masking and interdependence in dark adaptation and diabetes in the rat. Graefes Arch Clin Exp Ophthalmol 245:1335-1345
25. Lupi R, Mancarella R, Del Guerra S, Bugliani M, Del Prato S, Boggi U, Mosca F, Filipponi F, Marchetti P (2008) Effects of exendin-4 on islets from type 2 diabetes patients. Diabetes Obes Metab 10:515-519
26. Madsen-Bouterse SA, Kowluru RA (2008) Oxidative stress and diabetic retinopathy: Pathophysiological mechanisms and treatment perspectives. Rev Endocr Metab Disord 9:315-327
27. Malendowicz LK, Macchi C, Nussdorfer GG, Nowak KW, Zyterska A, Ziolkowska A (2003) Effects of prolonged exendin-4 administration on entero-insular axis of normal and streptozotocin-induced diabetic rats. Int J Mol Med 11:763-766
28. Malendowicz LK, Neri G, Nussdorfer GG, Nowak KW, Zyterska A, Ziolkowska A (2003) Prolonged exendin-4 administration stimulates pituitary-adrenocortical axis of normal and streptozotocin-induced diabetic rats. Int J Mol Med 12:593-596
29. Marmor MF, Holder GE, Seeliger MW, Yamamoto S (2004) Standard for clinical electroretinography (2004 update). Doc Ophthalmol 108:107-114
30. Nauck MAKN, Ørskov C, Holst JJ, Willms B, Creutzfeldt W (1993) Normalization of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741-744
31. P Schlatter CB, Drewe J, Gutmann H (2007) Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regulatory Peptides 141:120-128
32. Pradeepa R, Anitha B, Mohan V, Ganesan A, Rema M (2008) Risk factors for diabetic retinopathy in a South Indian Type 2 diabetic population - the Chennai Urban Rural Epidemiology Study (CURES) Eye Study 4. Diabet Med 25:536-542
33. Premalatha GVK, Deepa R et al (2002) Prevalence of non-diabetic renal disease in type 2 diabetic patients in a diabetes centre in Southern India. J Assoc Physicians India 50:1135-1139
34. Sakai H, Tani Y, Shirasawa E, Shirao Y, Kawasaki K (1995) Development of electroretinographic alterations in streptozotocin-induced diabetes in rats. Ophthalmic Res 27:57-63
35. Strauss A, Moskalenko V, Chodnevskaja I, Timm S, Thiede A, Otto C, Ulrichs K (2008) Exendin-4 improves the oral glucose tolerance in diabetic rats: Pancreas regeneration, better function of pancreatic islets, or impaired glucose uptake? Transplant Proc 40:533-535
36. Sundling V, Gulbrandsen P, Jervell J, Straand J (2008) Care of vision and ocular health in diabetic members of a national diabetes organization: A cross-sectional study. BMC Health Serv Res 8:159
37. Szayna M, Doyle ME, Betkey JA, Holloway HW, Spencer RGS, Greig NH, Egan JM (2000) Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 141:1936-1941
38. Vadala M, Anastasi M, Lodato G, Cillino S (2002) Electroretinographic oscillatory potentials in insulin-dependent diabetes patients: A long-term follow-up. Acta Ophthalmol Scand 80:305-309
39. Wong TY, Cheung N, Tay WT, Wang JJ, Aung T, Saw SM, Lim SC, Tai ES, Mitchell P (2008) Prevalence and Risk Factors for Diabetic Retinopathy. The Singapore Malay Eye Study. Ophthalmology [June 25, Epub ahead of print]
40. Xu G, Kaneto H, Laybutt DR, Duvivier-Kali VF, Trivedi N, Suzuma K, King GL, Weir GC, Bonner-Weir S (2007) Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: Possible contribution to impaired incretin effects in diabetes. Diabetes 56:1551-1558
41. Zhang J, Wu Y, Jin Y, Ji F, Sinclair SH, Luo Y, Xu G, Lu L, Dai W, Yanoff M, Li W, Xu G-T (2008) Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes. Invest Ophthalmol Vis Sci 49:732-742